Insulet Corporation (PODD)

Healthcare
Medical Devices
United States
Yahoo Finance  •  Trading View  •  Company site
Price
$252.70
▲ 0.29 (0.11%)
Market Cap
$17,788,192,768
Shares: 70,645,161.29
P/E
N/A
P/B: N/A
ROE
6.33%
Current Ratio: 2.87
Fundamentals Score
49 (NEUTRAL)

Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Headquarters: 100 Nagog Park, Acton, MA, 01720, United States  |  Employees: 3900  |  Website: insulet.com
Key Contacts
IR / Phone: 978 600 7000
Exchange: NMS
Industry: Medical Devices
Quick Financial Snapshot
Revenue$706,300,000
Net Income$87,600,000
Free Cash Flow$94,700,000
Book Value / ShareN/A

Balance Sheet & Liquidity

Total Liabilities$1,645,100,000
Total Equity$1,384,100,000
Debt / EquityN/A
Current Ratio2.87
Interest CoverageN/A
Working CapitalN/A

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)N/A
Industry P/EN/A
Forward P/E40.89
P/BN/A
Price / SalesN/A
P / FCFN/A
EV / EBITDAN/A
Graham NumberN/A
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin 72.22%
Operating Margin N/A
Net Margin N/A
ROIC N/A
Asset Turnover N/A

Automated Fundamental Signals (Score: 49)

Passed
  • Price CAGR 20.95%
  • Gross Margin 72.2%
  • Debt/Equity ratio
  • Operating Margin 16.7%
  • Positive Free Cash Flow
  • Current Ratio
Failed
  • EPS shows upward trend
  • EPS CAGR -17.60%
  • CapEx intensity
  • Debt/EBITDA
  • DCF valuation (Overvalued)

Price Chart (Candlestick)

Technical Analysis (Score: 50)

RSI (14)35.76
SMA 50281.31
SMA 200304.83
MACD-10.91
Signal NEUTRAL
RSI 35.8, SMA trend bearish, momentum -11.1%.

Governance & Management

Governance scores: Audit: 6 | Board: 5 | Compensation: 8 | Shareholder Rights: 9
Executive Team
NameTitle
Ms. Flavia H. Pease Executive VP & CFO (1973)
Mr. Eric Benjamin Executive VP & COO (1983)
Mr. John Wodick Kapples J.D. Senior VP & General Counsel (1960)
Ms. Ashley A. McEvoy CEO, President & Director (1971)
Mr. Amit Guliani Senior VP & CTO (—)
Ms. Clare Trachtman Vice President of Investor Relations (—)
Ms. Laetitia Cousin Senior VP of Regulatory Affairs, Quality Assurance & Compliance (1976)
Ms. Angela Geryak Wiczek Senior Director of Corporate Communications (—)
Governance data last updated: 2/1/2026

Latest News

No news available for this company.

← Back